Arabic Arabic English English French French German German
dark

Bioasis Announces Positive Results From an Efficacy Study of xB3™-IL-1RA in a Model of Multiple Sclerosis

BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), today announced positive results from an efficacy study of a blood-brain barrier penetrant interleukin-1 receptor inhibitor in a preclinical rodent model of multiple sclerosis Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

“The Doctor Will See You Now” and Other Things Patients Won’t Hear Post-COVID

Next Post

Viewpoint Molecular Targeting(R) Partners with Industry Leader Pepscan to Accelerate Peptide Discovery Program

Related Posts
Total
0
Share